Veraxa Biotech is trading 7.89% up at $1.64 in pre-market; no new company-specific announcement was identified for September 16, 2026, and the immediate reason remains unclear.

  • Latest located corporate developments were the September 4 CFO appointment and an earlier research milestone, both too stale to clearly explain the move.
  • Broader U.S. indices are modestly higher, but not enough to establish a market-wide catalyst.